| Activation of BAD and translocation to mitochondria |  | 
    
        | AKT phosphorylates targets in the cytosol |  | 
    
        | AKT phosphorylates targets in the nucleus |  | 
    
        | AKT-mediated inactivation of FOXO1A |  | 
    
        | Butyrate Response Factor 1 (BRF1) destabilizes mRNA |  | 
    
        | CD28 dependent PI3K/Akt signaling |  | 
    
        | Constitutive PI3K/AKT Signaling in Cancer |  | 
    
        | CTLA4 inhibitory signaling |  | 
    
        | deactivation of the beta-catenin transactivating complex |  | 
    
        | Downregulation of ERBB2:ERBB3 signaling |  | 
    
        | eNOS activation |  | 
    
        | G beta:gamma signalling through PI3Kgamma |  | 
    
        | GPVI-mediated activation cascade |  | 
    
        | Integrin alphaIIb beta3 signaling |  | 
    
        | KSRP destabilizes mRNA |  | 
    
        | Negative regulation of the PI3K/AKT network |  | 
    
        | PIP3 activates AKT signaling |  | 
    
        | Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation |  | 
    
        | Translocation of GLUT4 to the plasma membrane |  | 
    
        | VEGFR2 mediated vascular permeability |  |